Loading stock data…
$0.81-0.08 (-8.76%)
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health.
Ocugen, Inc. in the Healthcare sector is trading at $0.81 with a market capitalization of $458M. Wall Street consensus targets $12.17 (6 analysts), implying a +1406.1% move over the next 12 months. The stock is currently near its 52-week low of $0.79, remaining 45.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.49M↓ | $1.53M↑ | -$193,000↓ | $1.75M↑ | $1.37M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$16.44M↑ | -$17.84M↓ | -$17.00M↑ | -$17.63M↓ | -$13.79M |
| Net Income | -$24.88M↓ | -$19.18M↓ | -$17.71M↑ | -$20.05M↓ | -$14.74M |
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene thera...